<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02559869</url>
  </required_header>
  <id_info>
    <org_study_id>2015P000140</org_study_id>
    <nct_id>NCT02559869</nct_id>
  </id_info>
  <brief_title>Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis</brief_title>
  <acronym>TRACK-ALS</acronym>
  <official_title>Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Methodist Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ALS Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, 18-month study, which aims to identify imaging and biofluid biomarkers&#xD;
      in people with ALS to expand the understanding of ALS pathology, treatment targets, disease&#xD;
      progression, and anatomical differences between different disease phenotypes. This pilot&#xD;
      project is tailored to produce imaging tools that will allow researchers to conduct future&#xD;
      ALS clinical trials more efficiently which may in turn impact the pace for ALS drug&#xD;
      discovery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this trial, approximately 200 subjects will participate in this study from 2 Northeast ALS&#xD;
      Consortium (NEALS) centers in the United States. Fifty (50) ALS participants will be age and&#xD;
      gender matched to 50 participants with no known neurological disorder (healthy controls). Of&#xD;
      these, twenty five (25) ALS participants will be age (Â±5 years) gender and binding affinity&#xD;
      (TSPO) matched to 25 healthy controls.&#xD;
&#xD;
      During the enrollment period 200 participants will be screened and 100 participants will&#xD;
      ultimately be scanned. There will be a maximum allowed time of 45 days between the screening&#xD;
      and baseline visits (1st scan). All 100 subjects will undergo MRI scanning and clinical&#xD;
      assessment at the Baseline Visit. Healthy control participants will have no further follow-up&#xD;
      visits once they have completed their participation in the screening and baseline visits.&#xD;
      Only 50 subjects from this sample will undergo PET scanning. The ALS participants will return&#xD;
      for follow-up MRI scanning and clinical assessments every three months and follow-up PET&#xD;
      scanning every 6 months over a 12-month period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">June 28, 2019</completion_date>
  <primary_completion_date type="Actual">June 28, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measure &amp; localize brain inflammation in people with ALS via [18F] GE-180 PET imaging.</measure>
    <time_frame>12 months</time_frame>
    <description>Aim 1 will be accomplished by obtaining [18F] GE-180 PET imaging from 25 people with ALS compared to 25 age, gender, and binding affinity matched healthy volunteers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Define anatomical, structural, and functional changes in the brain via MRI of ALS Subjects vs. Healthy Controls at Baseline</measure>
    <time_frame>12 months</time_frame>
    <description>Aim 1 will be accomplished by obtaining state of-the-art MRI acquisition sequences from 50 people with ALS compared to 50 MRI age- and gender-matched healthy volunteers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine systemic inflammatory factors that may modify the progression or other clinical or imaging correlates of ALS.</measure>
    <time_frame>12 months</time_frame>
    <description>Blood from 100 subjects will be studied to quantitate circulating pro- and anti-inflammatory monocyte/macrophage and T cells, with results to be correlated with neuroimaging and evaluated as potential biomarkers of disease progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the longitudinal changes in brain inflammation in people with ALS in correlation with ALS severity and rate of progression.</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical and [18F] GE-180 PET imaging data will be collected every 6 months from the 25 people with ALS for at least 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the longitudinal changes in the anatomical, structural, and functional measures in people with ALS, and build ALS prediction models using the clinical and MRI data.</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical and MRI data will be collected every 3 months from 50 people with ALS for at least 12 months.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">86</enrollment>
  <condition>Amyotrophic Lateral Sclerosis (ALS)</condition>
  <arm_group>
    <arm_group_label>Amyotrophic Lateral Sclerosis (ALS)</arm_group_label>
    <description>Subjects will be diagnosed with possible, probable, probable-lab supported, or definite ALS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>Subjects with no known neurological disorder.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F] GE-180</intervention_name>
    <description>PET Tracer Ligand</description>
    <arm_group_label>Amyotrophic Lateral Sclerosis (ALS)</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <other_name>ligand</other_name>
    <other_name>PET Tracer</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      iPSC Line Generation, DNA, Inflammatory Markers, Plasma, CSF&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Approximately 200 subjects will be screened and approximately 100 subjects will be&#xD;
        enrolled. Fifty (50) subjects will be diagnosed with possible, probable, probable-lab&#xD;
        supported, or definite ALS, fifty (50) subjects will have no known neurological disease.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Study subjects meeting all of the following criteria will be allowed to enroll in the&#xD;
        study:&#xD;
&#xD;
          1. Male or female, aged 18 to 80&#xD;
&#xD;
          2. Medically safe to undergo MRI scans&#xD;
&#xD;
          3. Able to safely lie supine for at least 90 minutes in the opinion of the Site&#xD;
             Investigator&#xD;
&#xD;
          4. Capable of providing informed consent and following trial procedures&#xD;
&#xD;
          5. Geographically accessible to the site&#xD;
&#xD;
        ALS subjects must also meet the following criteria:&#xD;
&#xD;
          1. Sporadic or familial ALS diagnosed as possible, laboratory-supported probable,&#xD;
             probable, or definite as defined by modified El Escorial criteria&#xD;
&#xD;
          2. ALS Cognitive Behavioral Screen score &gt;10 on the cognitive scale and/or &gt;32 on the&#xD;
             behavioral scale&#xD;
&#xD;
        Those ALS subjects participating in the optional lumbar puncture portion of the study must&#xD;
        also meet the following criteria:&#xD;
&#xD;
        1. Subjects medically able to undergo lumbar puncture (LP) as determined by the&#xD;
        investigator (i.e., no bleeding disorder, allergy to local anesthetics, a skin infection at&#xD;
        or near the LP site, or evidence of high intracranial pressure).&#xD;
&#xD;
        For those subjects participating in the PET scan portion of the study, subjects must also&#xD;
        meet the following criteria:&#xD;
&#xD;
          1. Medically safe to undergo PET scans&#xD;
&#xD;
          2. No prior radiation exposure that exceeds the site's current guidelines&#xD;
&#xD;
          3. No known allergy to any components of the tracer&#xD;
&#xD;
          4. Baseline ECG values are within normal range&#xD;
&#xD;
          5. Subjects must meet main study entry criteria&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Study subjects meeting any of the following criteria during screening evaluations will be&#xD;
        excluded from entry into the study:&#xD;
&#xD;
          1. Any contraindication to undergo MRI studies such as&#xD;
&#xD;
               1. History of a cardiac pacemaker or pacemaker wires&#xD;
&#xD;
               2. Metallic particles in the body&#xD;
&#xD;
               3. Vascular clips in the head&#xD;
&#xD;
               4. Prosthetic heart valves&#xD;
&#xD;
               5. Claustrophobia&#xD;
&#xD;
          2. Diagnosis of Parkinson's disease or Alzheimer's disease&#xD;
&#xD;
          3. Diagnosis of renal failure&#xD;
&#xD;
          4. Have active or chronic autoimmune disease (such as hepatitis or HIV), infection, or&#xD;
             taking immunosuppressive medications such as steroids, cyclophosphamide, etc.&#xD;
&#xD;
          5. Presence of diaphragm pacing system (DPS)&#xD;
&#xD;
          6. The presence of unstable psychiatric disease, cognitive impairment, or dementia that&#xD;
             would impair ability of the subject to provide informed consent, according to SI&#xD;
             judgment&#xD;
&#xD;
          7. Pregnant women or women currently breastfeeding&#xD;
&#xD;
          8. Anything that, in the opinion of the investigator, would place the subject at&#xD;
             increased risk or preclude the subject's full compliance with or completion of the&#xD;
             study&#xD;
&#xD;
        In addition, any subject meeting any of the following criteria during screening evaluations&#xD;
        will be excluded from entry into the PET portion of the study:&#xD;
&#xD;
          1. Radiation exposure that exceeds the site's current guidelines&#xD;
&#xD;
          2. Low affinity TSPO binders determined by having a Thr/Thr polymorphism in the TSPO gene&#xD;
             (rs6971) at the Screening Visit&#xD;
&#xD;
        Women of Childbearing Potential (WOCBP) For the purposes of this study, women of child&#xD;
        bearing potential are defined as all women who are capable of becoming pregnant, unless&#xD;
        they meet one of the following criteria:&#xD;
&#xD;
          -  12-months post-menopausal&#xD;
&#xD;
          -  Post-hysterectomy&#xD;
&#xD;
          -  Surgically sterile&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suma Babu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Masdeu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Houston Methodist Neurological Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://alsconsortium.org</url>
    <description>NEALS website (Northeast ALS Consortium)</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 23, 2015</study_first_submitted>
  <study_first_submitted_qc>September 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2015</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Suma Babu</investigator_full_name>
    <investigator_title>Co-Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Biofluid</keyword>
  <keyword>ALS</keyword>
  <keyword>MRI</keyword>
  <keyword>PET</keyword>
  <keyword>Imaging</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>TRACK ALS</keyword>
  <keyword>pathology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

